{"id":"W4290994087","doi":"10.1136/annrheumdis-2022-eular.2468","title":"POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Secukinumab; Placebo; Oncology; Arthritis; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001033713,0.0007221028,0.00108214,0.0001723369,0.0002466156,0.0009734715,0.0002190344,0.0007026089,0.003803128],"category_scores_gemma":[0.0009706218,0.0001847189,0.0008285543,0.0002108646,0.0002860719,0.0006749102,0.000158146,0.001303372,0.0007282651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003784609,"about_ca_system_score_gemma":0.000351836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002795329,"about_ca_topic_score_gemma":0.0007454182,"domain_scores_codex":[0.9996351,0.0001369178,0.0000307561,0.0000813462,0.00004315142,0.00007277507],"domain_scores_gemma":[0.9994523,0.0001719129,0.0001108552,0.00003115279,0.00004966272,0.0001841104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6179219,0.006578446,0.1476919,0.0007481488,0.002992623,0.0002764122,0.0001289841,0.002627362,0.04447602,0.0003525559,0.007311494,0.1688941],"study_design_scores_gemma":[0.1351174,0.267771,0.5533714,0.0002074879,0.004123772,0.001878853,0.0002239914,0.007760241,0.01403453,0.001195778,0.01413857,0.0001767987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941063,0.00255044,0.0001617075,0.0003692513,0.0001526145,0.0001181268,0.0005986445,0.00003697991,0.001905975],"genre_scores_gemma":[0.9969304,0.000461937,0.0002556738,0.0003250331,0.00009062639,0.00006741258,0.001080813,0.000007009702,0.0007809879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003803128,"threshold_uncertainty_score":0.01272273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03291885164253951,"score_gpt":0.3062609298272585,"score_spread":0.273342078184719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}